Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Accumulated Depreciation (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Accumulated Depreciation for 6 consecutive years, with $7.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation rose 40.69% to $7.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.0 million, a 40.69% increase, with the full-year FY2025 number at $7.0 million, up 40.69% from a year prior.
  • Accumulated Depreciation was $7.0 million for Q4 2025 at Janux Therapeutics, up from $6.5 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $7.0 million in Q4 2025 to a low of $131000.0 in Q4 2021.
  • A 5-year average of $3.3 million and a median of $2.9 million in 2023 define the central range for Accumulated Depreciation.
  • Peak YoY movement for Accumulated Depreciation: skyrocketed 641.98% in 2022, then surged 40.69% in 2025.
  • Janux Therapeutics' Accumulated Depreciation stood at $131000.0 in 2021, then surged by 641.98% to $972000.0 in 2022, then surged by 199.79% to $2.9 million in 2023, then skyrocketed by 69.94% to $5.0 million in 2024, then skyrocketed by 40.69% to $7.0 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Accumulated Depreciation are $7.0 million (Q4 2025), $6.5 million (Q3 2025), and $5.5 million (Q1 2025).